grant
Medical Health Broad Portfolio Research Career Scientist Award
Organization VA VETERANS ADMINISTRATION HOSPITALLocation RICHMOND, UNITED STATESPosted 1 Apr 2019Deadline 31 Mar 2031
VANIHUS FederalResearch GrantFY20262,4,D/2,4,5,TAKTAPAF-3APAF3AblationAkt proteinAlternate SplicingAlternative RNA SplicingAlternative SplicingApaf-3 proteinApoptosis-Related Cysteine Protease Caspase 9Apoptosis-Related Cysteine Protease Gene Caspase 9ApoptoticApoptotic Protease Activating Factor 3Apoptotic Protease Activating Factor 3 GeneApoptotic Protease MCH-6Apoptotic Protease MCH-6 GeneAreaArmed Forces PersonnelAsbestosAutomobile DrivingAwardC-K-RASCASP-9CASP9CASP9 ProteinCASP9 geneCancer CauseCancer Causing AgentsCancer EtiologyCancersCarcinogensCaspase-9 GeneCell BodyCell Communication and SignalingCell SignalingCell SurvivalCell ViabilityCellsCellular OncogeneCessation of lifeCheckpoint inhibitorChemoresistanceClinicDNA mutationDataDeathDiseaseDisorderDown-RegulationDrug resistanceEffectivenessEventExclusionExonsExposure toFosteringFoundationsGeneticGenetic ChangeGenetic defectGenetic mutationGlobal ChangeGoalsHealthHealth Care SystemsHeterogeneous-Nuclear Ribonucleoprotein LHigh Throughput AssayHumanICE-LAP6ICE-LAP6 GeneICE-LAP6 proteinICE-Like Apoptotic Protease 6ICE-Like Apoptotic Protease 6 GeneImmune checkpoint inhibitorImmune mediated therapyImmunologically Directed TherapyImmunotherapyIncidenceIntracellular Communication and SignalingIonizing Electromagnetic RadiationIonizing radiationIsoformsK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneK-ras mouse modelKRASKRAS2KRAS2 geneKi-RASKras mouse modelKras murine modelLKB1LKB1/STK11 GeneLaboratoriesLinkMCH6MaintenanceMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMch6 proteinMedicalMethodologyMilitaryMilitary PersonnelModern ManMolecularMolecular TargetMutationNSCLCNSCLC - Non-Small Cell Lung CancerNon-Polyadenylated RNANon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogene K-RasOncogenesisOncogensOralOutcomePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPhosphorylationProbabilityProtein IsoformsProtein Kinase BProtein PhosphorylationProto-Oncogene Proteins c-aktProto-OncogenesPulmonary CancerPulmonary malignant NeoplasmRAC-PK proteinRASK2RNARNA Gene ProductsRadiation-Ionizing TotalResearchResistanceRibonucleic AcidSTK11STK11 geneScientistServicesSignal TransductionSignal Transduction SystemsSignalingSphingolipidsSurvival RateTherapeuticTobacco DependenceTranslationsValidationVeteransagent orangeanti-cancer researchbiological signal transductionc-ONCc-akt proteincancer initiationcancer researchcareercaspase-9ceramide 1-phosphateceramide kinasechemoresistantchemotherapy resistancechemotherapy resistantdrivingdrug resistantex-smokerformer smokergenome mutationhigh riskhigh throughput screeninghnRNP Limmune check point inhibitorimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedindividualized cancer careindividualized oncologyinhibitorinnovateinnovationinnovativeionizing outputkinase inhibitorliver kinase B1loss of functionloss of function mutationlung cancerlung cancer celllung tumorigenesismalignancymilitary populationmilitary serviceneoplasm/cancernew chemical entitynew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncogenic agentpalliativepatient oriented outcomespersonalized oncologypre-clinicalpre-clinical studyprecision cancer careprecision cancer medicineprecision oncologypreclinicalpreclinical studyproto-oncogene protein RACproto-oncogene protein aktprotooncogenerac protein kinaserelated to A and C-proteinresistance mechanismresistance to Drugresistantresistant mechanismresistant to Drugstandard of caresystemic inflammationsystemic inflammatory responsetherapeutic outcometherapy outcometobacco addictiontobacco dependenttooltranslationtumortumorigenesistumorigenesis in the lungv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologvalidations
Description preview
Lung cancer is the leading cause of cancer death for veterans, and non-small cell lung cancer (NSCLC) represents
the majority with a poor 5-year survival rate (~23%). Many veterans also acquire tobacco addiction during military
service fostering a large percentage of high-risk current & former smokers in the VA Health Care System. Lung
cancer is…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click